Drug development pipeline
Our lead program targets diabetic foot ulcers (DFU) and venous leg ulcers (VLUs), two conditions that affect millions of people and drive billions in healthcare costs each year.
Beyond DFUs, we are exploring plasminogen’s potential in other areas where healing fails or infection persists.
Infections, including antibiotic-resistant bacteria
Scarring and soft tissue regeneration
Periodontitis
Idiopathic pulmonary fibrosis
Each represents a high-need area where plasminogen offers both biological rationale and early preclinical promise.
